Risk factor
Good trading liquidity
Profitability factor
Favourable analyst view
About
Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including Sales, Contract Development & Manufacturing Organization (CDMO), and other ancillary services. Bora produces and markets a diverse range of medicines, from generic and proprietary brand-name drugs to over-the-counter (OTC) remedies. Beyond its in-house portfolio, the company provides extensive contract development and manufacturing solutions. These CDMO services cover all stages of pharmaceutical development, clinical and commercial production, specialized packaging and serialization, rigorous analytical and microbiological quality control, and expert guidance on regulatory compliance. Furthermore, Bora's offerings extend to nutritional supplements, skincare products, and various biotechnical services. The company distributes its goods directly to healthcare facilities such as clinics, pharmacies, and pharmacy chains, as well as to drugstores. It also leverages distributors to supply larger institutions like medical centers, corporate and public hospitals, and regional and district hospitals. Established in 2007, Bora Pharmaceuticals Co., LTD. is based in Taipei City, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV
Target Price
The average target price of 6472.TW is 682 and suggests 61.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to in